The Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai is designed to meet the special needs of cancer patients and their families. Nearly 3,000 patients come to see the nearly 450 doctors at Cedars-Sinai who are experts in treating more than 100 types of cancer.
The institute relies on a team of specialists to review each case. These specialists combine expertise, knowledge and resources to provide a wide range of diagnostic and treatment services. Board certified doctors are available in all areas of cancer diagnosis and treatment. These include medical oncology, radiation oncology, gynecologic oncology, pediatric oncology, surgical oncology, plastic and reconstructive surgery and bone marrow and stem cell transplantation.
Our scientists continually add to the growing knowledge base in cancer research. They are learning more about the biology of prostate cancer through new gene-chip technology. Women's cancer researchers are expanding what we know about ovarian, uterine, cervical and vulvar cancer through 25 clinical trials.
Cedars-Sinai is the only cancer center in the Los Angeles area that is available 24 hours a day. The center also helps cancer patients and families with their recovery and rehabilitation needs.
Services provided by the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai include:
- Chemo and radiation therapy
- Psycho-social services
- Diagnostic imaging
- Laboratory
- Nutritional support
- Pain management
- Pediatric and gynecologic treatment
- Pharmacy
- Psychosocial services
- Surgery, including plastic and reconstructive
- Surgery, including plastic and reconstructive
- Symptom management
Just as no two men are alike, at Cedars-Sinai, our approach to treating prostate cancer is as individual as the men who come to us.
The Louis Warschaw Prostate Cancer Center is the first of its kind in Los Angeles. Our team of doctors will provide you with expert opinions from diverse disciplines, including urologists, oncologists, diagnostic imaging specialists, nuclear medicine specialists, radiation therapists, pathologists, nutritionists, nurses and therapists. This team meets together for each case to offer points of view on treatment. This ensures that all treatment avenues have been explored.
Our blend of specialized doctors and services offer options that best fit each patient's needs. From diagnosis to treatment, our patients get the information they need to make the best decisions.
The Prostate Cancer Center at Cedars-Sinai provides a wide array of cutting-edge treatments.
Our advanced research laboratory conducts pre-clinical drug studies. It also develops new therapies and supports many clinical trials. Much of the research focuses on the biology of prostate cancer. It also includes gene chip analysis. With this information, our doctors can better understand the specific type of prostate cancer a patient has and the best treatment for him. Each man's treatment is customized to his needs, his health and the type of prostate cancer he has.
Cedars-Sinai provides women with a full spectrum of breast cancer services from education, screening and treatment to rehabilitation and supportive care. We blend the finest resources with the expertise of our health care professionals to provide efficient, compassionate care. The Center brings new treatments from the laboratory to patients very quickly. Thanks to the Center's research, prostate cancer patients can take advantage of new technologies and medicines not available elsewhere.
Worldwide, breast cancer is the third most common type of cancer, and by far the most often diagnosed among women.
Our doctors and researchers at the Saul and Joyce Brandman Breast Center are always looking for better ways to treat and manage the disease. We continue to explore how breast cancer develops and why. We also seek out new anticancer drugs and treatment methods. Many of the women who seek care here benefit from this research by participating in clinical trials.
The Gilda Radner Cancer Detection Program follows women who are at high risk for ovarian cancer. A woman's ability to join this study is based on her own and her family history of breast or ovarian cancer. Women receive screening with ultrasound and blood tests, as well as genetic counseling.
Founded in 1981, the program now has mature data for more than 1,200 women. Our results have helped to shape the current National Institutes of Health recommendations for ovarian cancer screening.
The program now focuses on women who have an inherited mutation in one of the recently discovered BRCA genes. These candidates are now known to be at the highest risk for ovarian cancer.
As a result, the Gilda Radner screening protocol now includes new tests. For example, we now use a three-dimensional ultrasound, as well as novel blood tests such as LPA (lysophosphaditic acid), a promising new tumor biomarker.
